Vertex Pharmaceuticals
VRTX
Vertex Pharmaceuticals (VRTX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $4.73
- EPS estimate
- $4.74
- EPS surprise
- −0.23%
- Revenue surprise
- +3.25%
- Revenue
- $3.3B
- Revenue estimate
- $3.2B
- Reported
- Aug 3, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 3, 2026 | $4.74 | $4.73 | −0.23% | $3.3B | SEC |
| Q1 2026 | May 4, 2026 | $4.24 | $4.47 | +5.35% | $3.0B | SEC |
| Q4 2025 | Feb 12, 2026 | $5.11 | $5.03 | −1.58% | $3.2B | SEC |
| Q3 2025 | Nov 3, 2025 | $4.57 | $4.80 | +4.96% | $3.1B | SEC |
| Q2 2025 | Aug 4, 2025 | $4.29 | $4.52 | +5.40% | $2.9B | SEC |
| Q1 2025 | May 5, 2025 | $4.32 | $4.06 | −5.95% | $2.8B | SEC |
| Q4 2024 | Feb 10, 2025 | $4.02 | $3.98 | −0.90% | $2.9B | SEC |
| Q3 2024 | Nov 4, 2024 | $4.08 | $4.38 | +7.41% | $2.8B | SEC |
| Q2 2024 | Aug 1, 2024 | −$11.63 | −$12.83 | −10.36% | $2.6B | SEC |
| Q1 2024 | May 6, 2024 | $4.07 | $4.76 | +16.87% | $2.7B | SEC |
| Q4 2023 | Feb 5, 2024 | $4.07 | $4.20 | +3.27% | $2.5B | SEC |
| Q3 2023 | Nov 6, 2023 | $3.93 | $4.08 | +3.72% | $2.5B | SEC |
| Q2 2023 | Aug 1, 2023 | $3.86 | $3.89 | +0.80% | $2.5B | SEC |
| Q1 2023 | May 1, 2023 | $3.01 | $3.05 | +1.23% | $2.4B | SEC |
| Q4 2022 | Feb 7, 2023 | $3.53 | $3.76 | +6.50% | $2.3B | SEC |
| Q3 2022 | Oct 27, 2022 | $3.61 | $4.01 | +11.00% | $2.3B | SEC |
| Q2 2022 | Aug 4, 2022 | $3.47 | $3.60 | +3.64% | $2.2B | SEC |
| Q1 2022 | May 5, 2022 | $3.57 | $3.52 | −1.38% | $2.1B | SEC |
| Q4 2021 | Jan 26, 2022 | $3.29 | $3.37 | +2.53% | $2.1B | SEC |
| Q3 2021 | Nov 2, 2021 | $3.09 | $3.56 | +15.22% | $2.0B | SEC |
Quarterly revenue
Frequently asked questions
When did Vertex Pharmaceuticals (VRTX) last report earnings?
Vertex Pharmaceuticals last reported on Aug 3, 2026, covering fiscal Q2 2026.
Did VRTX beat earnings estimates?
No. Vertex Pharmaceuticals reported EPS of $4.73 for Q2 2026 against a $4.74 estimate — a 0.23% miss.
How much revenue did VRTX report last quarter?
Vertex Pharmaceuticals reported $3.3B in revenue for Q2 2026, against a consensus estimate of $3.2B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.